Insmed (INSM) Cash from Operations (2010 - 2026)
Insmed (INSM) posted quarterly Cash from Operations of 222738000.0 for Q1 2026, up 15.01% year-over-year from 193661572.01 in Q1 2025, and up 10.04% quarter-over-quarter from 247596000.0 in Q4 2025.
Insmed (INSM) Cash from Operations (2010 - 2026) Analysis & Trends
Insmed's Cash from Operations history runs 17 years deep, the most recent figure standing at 222738000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 15.01% year-over-year to 222738000.0; the TTM figure through Mar 2026 stood at 895664000.0 (down 17.55% YoY), while the FY2025 annual figure was 935014000.0, down 36.72% from the prior year.
- Cash from Operations for Q1 2026 stood at 222738000.0, up from 247596000.0 in the prior quarter.
- The five-year high for Cash from Operations was 89828000.0 in Q3 2022, with the low at 262088000.0 in Q1 2025.
- The 5-year median for Cash from Operations is 146303000.0 (2023), against an average of 163430588.24.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations rose 18.02% in 2022, then slumped 67.19% in 2025.
- Insmed's Cash from Operations stood at 103149000.0 in 2022, then declined by 26.83% to 130819000.0 in 2023, then tumbled by 49.81% to 195979000.0 in 2024, then dropped by 26.34% to 247596000.0 in 2025, then rose by 10.04% to 222738000.0 in 2026.
- Business Quant data shows INSM's Cash from Operations at 222738000.0 in Q1 2026, 247596000.0 in Q4 2025, and 219761000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -270.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -88.83 Mn |
| Jun 30, 2026 | -88.83 Mn |
| Mar 31, 2026 | -222.74 Mn |
| Mar 31, 2026 | -222.74 Mn |
| Dec 31, 2025 | -247.60 Mn |
| Dec 31, 2025 | -247.60 Mn |
| Sep 30, 2025 | -219.76 Mn |
| Sep 30, 2025 | -219.76 Mn |
| Jun 30, 2025 | -205.57 Mn |
| Jun 30, 2025 | -205.57 Mn |
| Mar 31, 2025 | -262.09 Mn |
| Mar 31, 2025 | -262.09 Mn |
| Dec 31, 2024 | -195.98 Mn |
| Dec 31, 2024 | -195.98 Mn |
| Sep 30, 2024 | -180.92 Mn |
| Sep 30, 2024 | -180.92 Mn |
| Jun 30, 2024 | -122.95 Mn |
| Jun 30, 2024 | -122.95 Mn |
| Mar 31, 2024 | -184.04 Mn |
| Mar 31, 2024 | -184.04 Mn |